Table 1 Baseline characteristics of the study population

age [years]

43.3 (±12.6)

gender (men/women) [n (%)]

23 (54.8%)/19 (43.2%)

time on dialysis until RT [months]

36.18 (±22.72)

haemoglobin [g/dl]

12.25 (±3.67)

natrium [mmol/l]

139.0 (±2.71)

potassium [mmol/l]

4.7 (±1.31)

magnesium [mmol/l]

0.99 (±0.28)

calcium [mmol/l]

2.54 (±0.24)

phosphorus [mmol/l]

1.68 (±0.49)

Ca X P [mg²/dl²]

52.47 (±13.94)

parathormone [pg/ml]

734.3 (±656.8)

creatinine [μmol/l]

539.24 (±245.75)

eGRF [ml/min/1,73 m²]

10.9 (±7.68)

urea [mmol/l]

9.74 (±5.72)

total protein [g/l]

75.0 (±14.3)

albumin [g/l]

4.6 (±1.13)

hs-CRP [mg/l]

2.12 (±2.22)

total cholesterol [mg/dl]

219.0 (±67.2)

LDL-cholesterol [mg/dl]

131.0 (±44.15)

HDL-cholesterol [mg/dl]

66.1 (±24.55)

triglycerides [mg/dl]

214.3 (±67.64)

glucose [mg/dl]

90.77 (±47.19)

troponin T [μg/l]

0.018 (±0.037)

myoglobin [ng/ml]

183.5 (±171.1)

creatine kinase [U/l]

81.1 (±86.2)

creatine kinase myocardial bound [U/l]

17.4 (±8.12)

 ACE-inhibitors/sartans [n (%)]

0 (%)

 calcium blockers [n (%)]

40 (95.2%)

 beta-blockers [n (%)]

23 (54.8%)

 alfa-blockers [n (%)]

5 (11.9%)

 clonidine [n (%)]

31 (73.8%)

 statins [n (%)]

3 (7.1%)

 methylprednisolone [n (%)]

42 (100%)

 mycophenolate mofetil [n (%)]

42 (100%)

 cyclosporine [n (%)]

21 (50%)

 tacrolimus [n (%)]

21 (50%)